MDRNA has entered into an agreement with Roche in which Roche will obtain a non-exclusive license to a portion of MDRNA's technology platform for the development of RNAi-based therapeutics. "This agreement provides us the necessary resources to continue to pursue multiple, non-exclusive research collaborations, as well as future financing opportunities," said MDRNA CEO J. Michael French in a statement. Terms of the agreement were not disclosed. MDRNA's release